

## **CURRICULUM VITAE**

### **1. GENERAL DATA**

#### **1.1 PERSONAL DATA**

Date of Birth: 20 November 1986  
Place of Birth: Verona  
Address: Via L. Carcereri 4/C 37042 Caldiero (VR)  
Citizenship: Italian

#### **1.2 EDUCATION**

2000-2005	High School course in science and IT "A. Messedaglia" Verona (final grade: 100/100)
2005 -2011	University of Verona, course of Medicine and Surgery
2012-2017	University of Verona, Post Graduate School of Rheumatology – Dir. Prof. Maurizio Rossini
2017 - ongoing	University of Verona, PhD – Dir. Prof. Maurizio Rossini

### 1.3 TITLES

- 19/10/2011 Degree in Medicine and Surgery (final grade: 110/110 cum laude)
- 17/07/2017 Medical Specialty Training in Rheumatology (final grade: 70/70 cum laude)

### 1.4 RECENT POSITION

Since July 2017 - ongoing	PhD researcher - Rheumatology Unit of University of Verona Research fellow - Rheumatology Unit of University of Verona
Since July 2017 – march 2020	Attending physician (medico gettonista) – Rheumatology Unit of University of Verona
April 2020 – July 2020	Attending physician for COVID-19 emergency, Pneumology COVID-19 Unit at Ospedale di Borgo Trento, Verona
July 2020 - ongoing	Attending physician (medico gettonista) – Rheumatology Unit of University of Verona

### 1.5 PREVIOUS POSITIONS

- **July 2010 – July 2012:** Volunteer Attendant Student - Rheumatology Unit of University of Verona

- **July 2012 – July 2017:** Resident Medical Doctor - Rheumatology Unit of University of Verona

## **2. CLINICAL ACTIVITIES**

Dr Angelo Fassio started his clinical activities at the University of Verona, where he achieved his Degree in Medicine in Surgery in 2011. He got his Medical Qualification in March 2012. Since March 2012, he attended at Rheumatology Unit of University of Verona. In July 2012 he started his Post Graduate School in Rheumatology in the same Unit. Here he received his training and joined all the various activities of the Unit, the hospital wards, covering also and the outpatient clinics:

- General Rheumatology
- Early arthritis
- Osteoporosis and bone metabolism
- Connective tissue diseases
- Musculoskeletal and Rheumatological ultrasound
- US-guided interventional procedures
- Night shifts and holiday shifts for the Rheumatology Unit and General Internal Medicine Division (Medicina ad indirizzo Immunoematologico ed Emocoagulativo – Ospedale G.B. Rossi Verona)

## **3. SCIENTIFIC PRODUCTION**

Dr. Fassio started his scientific activities Rheumatology Unit of University of Verona. His research was first in the field of osteoporosis and bone metabolic diseases. Then, in the physiopathology of rheumatic diseases involving bone (osteoimmunology, chronic regional pain syndrome-1, osteogenesis imperfecta, Paget's disease, rheumatoid arthritis, psoriatic arthritis, early arthritis, biologic treatments).

Since 2012 he has been working also as subinvestigator in research protocols and clinical trials for the treatment of rheumatic diseases (rheumatoid arthritis, psoriatic arthritis, osteoporosis, CRSP-1).

#### 4. SCIENTIFIC PUBLICATIONS

- On Scopus: author of 61 documents, 286 total citations, h-index: 11 (last update: 12/10/2020)

##### 4.1 INDEXED ARTICLES

1. 18F-fluoride PET/CT for detection of axial involvement in ankylosing spondylitis: correlation with disease activity, Idolazzi L, Salgarello M, Gatti D, Viapiana O, Vantaggiato E, **Fassio A**, et al. Ann Nucl Med. 2016 Aug;30(7):511.
2. Vitamin D: not just bone, but also immunity. Gatti D, Idolazzi L, **Fassio A**. Minerva Med. 2016 Jul 21;
3. Teriparatide and denosumab combination therapy and skeletal metabolism. Idolazzi L, Rossini M, Viapiana O, Braga V, **Fassio A**, Benini C, et al. Osteoporos Int. 2016 Jun 1;
4. . Pathogenesis of bone erosions in Rheumatoid Arthritis: not only inflammation. Rossini M, **Fassio A**, Idolazzi L, Viapiana O, Fracassi E, Adami G, Povino MR, Vitiello M, Gatti D J Rheum Dis Treat 2015, 1:2
5. Insight into the WNT system and its drug related response. Tamanini S, Idolazzi L, Gatti D, Viapiana O, **Fassio A**, Rossini M. Reumatismo. 2013;65(5):219–30.
6. Duration of treatment for osteoporosis. Reumatismo. Idolazzi L, **Fassio A**, Gatti D, Tamanini S, Viapiana O, Rossini M, et al. 2013;65(1):22–35.
7. The initiative on hip fractures of the Veneto Region. Rossini M, Caimmi C, Giannini S, Sella S, Mattarei A, Lovato R, Piazza I, **Fassio A**, Persi P, Benetollo PP, Adami S.Clin Cases Miner Bone Metab. 2012 Jan;9(1):45-9. Epub 2012 May 29
8. Idolazzi L, **Fassio A**, Gatti D, Tamanini S, Viapiana O, Rossini M, et al. Duration of treatment for osteoporosis. Reumatismo. 2013;65(1):22–35.
9. **Fassio A**, Idolazzi L, Jaber MA, Dartizio C, Viapiana O, Rossini M, Gatti D. The negative bone effects of the disease and of chronic corticosteroid treatment in premenopausal women affected by rheumatoid arthritis. Reumatismo. 2016; 9;68(2):65-71

10. Bone metabolism in patients with anorexia nervosa and amenorrhoea L. Idolazzi, M. El Ghoch, R. Dalle Grave, P. V. Bazzani, S. Calugi, A. **Fassio**, C. Caimmi, O. Viapiana, F. Bertoldo, V. Braga, M. Rossini, D. Gatti. Eating and weight disorders. 2016
11. A case of mandibular Paget's disease of the bone treated with intravenous neridronate. **Fassio A**, Idolazzi L, Maurizio R, Gatti D. Reumatismo. 2016
12. Periostin: The bone and beyond. Idolazzi L, Ridolo E, Fassio A, Gatti D, Montagni M, Caminati M, Martignago I, Incorvaia C, Senna G. Eur J Intern Med. 2016
13. Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone. Idolazzi L, **Fassio A**, Tripi G, Braga V, Viapiana O, Adami G, Rossini M, Gatti D. Clin Rheumatol. 2017
14. Drug-induced osteonecrosis of the jaw: the state of the art. **Fassio A**, Bertoldo F, Idolazzi L, Viapiana O, Rossini M, Gatti D. Reumatismo. 2017 May 22;69(1):9-15.
15. Long-term Effects of Neridronate in Adults with Osteogenesis Imperfecta: An Observational Three-Year Italian Study. Viapiana O, Idolazzi L, **Fassio A**, Orsolini G, Rossini M, Adami G, Bertoldo F, Gatti D. Calcif Tissue Int. 2017
16. Comment on: clinical efficacy of oral alendronate in ankylosing spondylitis: a randomised placebo-controlled trial. Giollo A, Gatti D, Viapiana O, Idolazzi L, **Fassio A**, Adami G, Rossini M. Clin Exp Rheumatol. 2017 Apr 18.
17. New strategies for the prevention and treatment of systemic and local bone loss; from pathophysiology to clinical application. **Fassio A**, Rossini M, Viapiana O, Idolazzi L, Benini C, Vantaggiato E, Gatti D. Curr Pharm Des. 2017 Jul 13.
18. Osteoporosis: an Independent Determinant of Bone Erosions in Rheumatoid Arthritis? Rossini M, Adami G, Viapiana O, Idolazzi L, Orsolini G, **Fassio A**, Giollo A, Gatti D. J Bone Miner Res. 2017 Jul 2.
19. Treatment with neridronate in children and adolescents with osteogenesis imperfecta: Data from open-label, not controlled, three-year Italian study. Idolazzi L, **Fassio A**, Viapiana O, Rossini M, Adami G, Bertoldo F, Antoniazzi F, Gatti D. Bone. 2017 Oct

20. Effects of secukinumab on serum adipocytokines: preliminary data. **Fassio A**, Gatti D, Gisondi P, Girolomoni G, Viapiana O, Giollo A, Zamboni M, Rossini M, Idolazzi L. *Reumatismo*. 2017 Sep 21;69(3):105-110.
21. Rheumatoid arthritis,  $\gamma\delta$  T cells and bisphosphonates. Rossini M, Adami G, Viapiana O, Idolazzi L, **Fassio A**, Giollo A, Caimmi C, Orsolini G, Gatti D. *Ann Rheum Dis*. 2017 Oct 26.
22. No Effects of Teriparatide on Joint Erosions in Rheumatoid Arthritis: An expected result. Adami G, Rossini M, Viapiana O, **Fassio A**, Idolazzi L, Orsolini G, Gatti D. *Arthritis Rheumatol*. 2017 Nov 28.
23. Bone Geometry, Quality, and Bone Markers in Children with Type 1 Diabetes Mellitus. Franceschi R, Longhi S, Cauvin V, **Fassio A**, Gallo G, Lupi F, Reinstadler P, Fanolla A, Gatti D, Radetti G. *Calcif Tissue Int*. 2017 Dec 30.
24. The obesity paradox and osteoporosis. **Fassio A**, Idolazzi L, Rossini M, Gatti D, Adami G, Giollo A, Viapiana O. *Eat Weight Disord*. 2018 Jun;23(3):293-302.
25. Anti-CCP antibodies and bone. Orsolini G, Viapiana O, Rossini M, Adami G, Caimmi C, **Fassio A**, Gatti D. *Arthritis Res Ther*. 2018 Apr 10;20(1):63.
26. The obesity paradox and osteoporosis. **Fassio A**, Idolazzi L, Rossini M, Gatti D, Adami G, Giollo A, Viapiana O. *Eat Weight Disord*. 2018 Jun;23(3):293-302.
27. Ultrasonography of the nail unit reveals quantitative and qualitative alterations in patients with psoriasis and psoriatic arthritis. Idolazzi L, Gisondi P, **Fassio A**, Viapiana O, Giollo A, Rossini M, Girolomoni G, Gatti D. *Med Ultrason*. 2018 May 2;20(2):177-184.
28. In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls. **Fassio A**, Idolazzi L, Viapiana O, Benini C, Vantaggiato E, Bertoldo F, Rossini M, Gatti D. *Clin Rheumatol*. 2017 Oct;36(10):2377-2381.
29. Parathyroid hormone is a determinant of serum Dickkopf-1 levels in ankylosing spondylitis. Orsolini G, Adami G, Rossini M, Ghellere F, Caimmi C, **Fassio A**, Idolazzi L, Gatti D, Viapiana O. *Clin Rheumatol*. 2018
30. Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes. Mantovani A, Sani E, **Fassio A**, Colecchia A, Viapiana O, Gatti D, Idolazzi L, Rossini M, Salvagno G, Lippi G, Zoppini G, Byrne CD, Bonora E, Targher G. *Diabetes*

Metab 2018

31. Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis? Orsolini G, Adami G, Rossini M, **Fassio A**, Giollo A, Caimmi C, Idolazzi L, Gatti D, Viapiana O. *Arthritis Res Ther*. 2018
32. Secukinumab produces a quick increase in WNT signalling antagonists in patients with psoriatic arthritis. **Fassio A**, Gatti D, Rossini M, Idolazzi L, Giollo A, Adami G, Gisondi P, Girolomoni G, Viapiana O. *Clin Exp Rheumatol*. 2019
33. Inhibition of tumor necrosis factor-alpha (TNF-alpha) in patients with early rheumatoid arthritis results in acute changes of bone modulators. **Fassio A**, Adami G, Gatti D, Orsolini G, Giollo A, Idolazzi L, Benini C, Vantaggiato E, Rossini M, Viapiana O. *Int Immunopharmacol*. 2019
34. Amino-Bisphosphonates and Cardiovascular Risk: A New Hypothesis Involving the Effects on Gamma-Delta T Cells. Giollo A, Rossini M, Gatti D, Adami G, Orsolini G, **Fassio A**, Caimmi C, Idolazzi L, Viapiana O. *J Bone Miner Res*. 2019
35. Effectiveness of influenza vaccine in TNF inhibitors treated patients: comment on the article by Burmester et al. Adami G, **Fassio A**, Orsolini G, Giollo A, Gatti D, Rossini M. *Ann Rheum Dis*. 2019
36. Association between increased carotid intima-media thickness and higher serum C-terminal telopeptide of type 1 collagen levels in post-menopausal women with type 2 diabetes. Mantovani A, Altomari A, **Fassio A**, Gatti D, Bonnet F, Targher G. *Diabetes Metab*. 2019
37. Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women. **Fassio A**, Adami G, Benini C, Vantaggiato E, Saag KG, Giollo A, Lippolis I, Viapiana O, Idolazzi L, Orsolini G, Rossini M, Gatti D. *Bone*. 2019
38. Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations. Orsolini G, Bultink IEM, Adami G, **Fassio A**, Viapiana O, Giollo A, Gatti D, Rossini M. *Ann Rheum Dis*. 2019
39. EFFECTS OF BIOLOGICAL AND TARGETED SYNTHETIC DMARDs ON BONE LOSS IN RHEUMATOID ARTHRITIS. Orsolini G, **Fassio A**, Rossini M, Adami G, Giollo A, Caimmi C, Idolazzi L, Viapiana O, Gatti D. *Pharmacol Res*. 2019

40. Vitamin D: no efficacy without deficiency. What's new? **Fassio A**, Rossini M, Gatti D. *Reumatismo*. 2019
41. Radiological features of knee joint synovial chondromatosis. Boninsegna E, **Fassio A**, Testoni M, Gatti D, Viapiana O, Mansueto G, Rossini M. *Reumatismo*. 2019
42. Nail ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review. **Fassio A**, Giovannini I, Idolazzi L, Zabotti A, Iagnocco A, Sakellariou G. *Clinical Rheumatology*, 2019
43. Ultrasonographic detection, definition and quantification of soft tissue oedema in psoriatic dactylitis. Tinazzi I, Idolazzi L, Zabotti A, Arancio L, Batticiotto A, Caimmi C, De Lucia O, **Fassio A**, Girolimetto N, Macchioni P, Murgo A, Sakellariou G, Iagnocco A. *Med Ultrason*. 2019
44. Ultrasonographic detection, definition and quantification of soft tissue oedema in psoriatic dactylitis. Tinazzi I, Idolazzi L, Zabotti A, Arancio L, Batticiotto A, Caimmi C, De Lucia O, **Fassio A**, Girolimetto N, Macchioni P, Murgo A, Sakellariou G, Iagnocco A. *Med Ultrason*. 2019
45. Osteoporosis in Rheumatic Diseases. Adami G, **Fassio A**, Rossini M, Caimmi C, Giollo A, Orsolini G, Viapiana O, Gatti D. *Int J Mol Sci*. 2019
46. Usefulness of CHA2 DS2 -VASc score to predict mortality and hospitalization in patients with inflammatory arthritis. Cioffi G, Viapiana O, Orsolini G, Idolazzi L, Fracassi E, Ognibeni F, Dalbeni A, Gatti D, Carletto A, **Fassio A**, Rossini M, Giollo A. *Int J Rheum Dis*. 2020
47. Acute Effects of Glucocorticoid Treatment, TNF $\alpha$  or IL-6R Blockade on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis: A Pilot Study. **Fassio A**, Adami G, Giollo A, Viapiana O, Malavolta N, Saviola G, Bortolotti R, Idolazzi L, Bertoldo F, Rossini M, Gatti D. *Calcif Tissue Int*. 2020
48. Pharmacological management of osteoporosis in postmenopausal women: The current state of the art. Gatti D, **Fassio A**. *J Popul Ther Clin Pharmacol*. 2019
49. Comments on Kanis et al.: Algorithm for the management of patients at low, high, and very high risk of osteoporotic fractures. Adami G, Rossini M, **Fassio A**, Viapiana O, Gatti D. *Osteoporos Int*. 2020
50. Vitamin D supplementation: much ado about nothing. Gatti D, Bertoldo F, Adami G, Viapiana O, Lello S, Rossini M, **Fassio A**. *Gynecol Endocrinol*. 2020



51. Cancer in adult patients with inflammatory arthritis is associated with high ascending aortic stiffness and left ventricular hypertrophy and diastolic dysfunction. Cioffi G, Viapiana O, Tarantini L, Ognibeni F, Orsolini G, **Fassio A**, Gatti D, Rossini M, Giollo A. Intern Emerg Med. 2020
52. Disease Activity and Anticitrullinated Peptide Antibody Positivity Predict the Worsening of Ventricular Function in Rheumatoid Arthritis. Cioffi G, Giollo A, Orsolini G, Idolazzi L, Dalbeni A, Ognibeni F, Fracassi E, Gatti D, **Fassio A**, Rossini M, Viapiana O. ACR Open Rheumatol. 2020
53. Pharmacokinetics of Oral Cholecalciferol in Healthy Subjects with Vitamin D Deficiency: A Randomized Open-Label Study. **Fassio A**, Adami G, Rossini M, Giollo A, Caimmi C, Bixio R, Viapiana O, Milleri S, Gatti M, Gatti D. Nutrients. 2020
54. Risk of fragility fractures in obesity and diabetes: a retrospective analysis on a nation-wide cohort. Adami G, Gatti D, Rossini M, Orsolini G, Pollastri F, Bertoldo E, Viapiana O, Bertoldo F, Giollo A, **Fassio A**. Osteoporos Int. 2020
55. Different fracture risk profile in patients treated with anti-osteoporotic drugs in real-life. Adami G, Giollo A, Rossini M, Orsolini G, Benini C, Viapiana O, Gatti D, **Fassio A**. Reumatismo. 2020
56. Could Previous Exposure to Nitrogen-Containing Bisphosphonates Mitigate Friendly Fire? Adami G, **Fassio A**, Giollo A, Orsolini G, Viapiana O, Gatti D, Rossini M. J Bone Miner Res. 2020 Sep 4. doi: 10.1002/jbmr.4163.
57. Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco *et al*. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases. Giollo A, Bertoldo E, Adami G, Cybulski AJ, **Fassio A**, Orsolini G, Idolazzi L, Gatti D, Viapiana O, Rossini M. Ann Rheum Dis. 2020 Sep 7;annrheumdis-2020-218845. doi: 10.1136/annrheumdis-2020-218845
58. Wnt Inhibitors and Bone Turnover Markers in Patients With Polymyalgia Rheumatica and Acute Effects of Glucocorticoid Treatment. **Fassio A**, Adami G, Idolazzi L, Giollo A, Viapiana O, Vantaggiato E, Benini C, Rossini M,

Dejaco C, Gatti D. *Front Med (Lausanne)*. 2020 Sep 9;7:551. doi: 10.3389/fmed.2020.00551

59. Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Type 2 Diabetes: A New Imaging Possibility and a New Biomarker. **Fassio A**, Adami G, Idolazzi L, Giollo A, Viapiana O, Bosco E, Negrelli R, Sani E, Sandri D, Mantovani A, Targher G, Rossini M, Gatti D. *Calcif Tissue Int*. 2020 Oct 12
60. Clinical profile and outcome of patients with chronic inflammatory arthritis and metabolic syndrome. Cioffi G, Viapiana O, Tarantini L, Orsolini G, Idolazzi L, Sonographer FO, Dalbeni A, Gatti D, **Fassio A**, Rossini M, Giollo A. *Intern Emerg Med*. 2020
61. Predictors and prognostic role of low myocardial mechano-energetic efficiency in chronic inflammatory arthritis. Cioffi G, Mancusi C, de Simone G, Ognibeni F, Orsolini G, Dalbeni A, Gatti D, **Fassio A**, Adami G, Rossini M, Viapiana O, Giollo A. *J Hypertens*. 2021
62. Recent Advances in Imaging for Diagnosis, Monitoring, and Prognosis of Psoriatic Arthritis. **Fassio A**, Matzneller P, Idolazzi L. *Front Med (Lausanne)*. 2020
63. Osteoporosis in Inflammatory Arthritides: New Perspective on Pathogenesis and Treatment. Rotta D, **Fassio A**, Rossini M, Giollo A, Viapiana O, Orsolini G, Bertoldo E, Gatti D, Adami G. *Front Med (Lausanne)*. 2020
64. Association between environmental air pollution and rheumatoid arthritis flares. Adami G, Viapiana O, Rossini M, Orsolini G, Bertoldo E, Giollo A, Gatti D, **Fassio A**. *Rheumatology (Oxford)*. 2021
65. Is central sensitization an important determinant of functional disability in patients with chronic inflammatory arthritides? Adami G, Gerratana E, Atzeni F, Benini C, Vantaggiato E, Rotta D, Idolazzi L, Rossini M, Gatti D, **Fassio A**. *Ther Adv Musculoskelet Dis*. 2021
66. Vitamin D and disease severity in coronavirus disease 19 (COVID-19). Adami G, Giollo A, **Fassio A**, Benini C, Bertoldo E, Bertoldo F, Orsolini G, Idolazzi L, Viapiana O, Giannini S, Passeri G, Tacconelli E, Micheletto C, Gatti D, Rossini M. *Reumatismo*. 2021
67. Left ventricular hypertrophy predicts poorer cardiovascular outcome in normotensive normoglycemic patients with rheumatoid arthritis. Cioffi G,

Viapiana O, Orsolini G, Ognibeni Sonographer F, Dalbeni A, Gatti D, Adami G, **Fassio A**, Rossini M, Giollo A. Int J Rheum Dis. 2021

68. Factors associated with referral for osteoporosis care in men: a real-life study of a nationwide dataset. Adami G, Gatti D, Rossini M, Giollo A, Bertoldo E, Viapiana O, Olivi P, **Fassio A**. Arch Osteoporos. 2021

69. The troubling liaison between cancer and metabolic syndrome in chronic inflammatory rheumatic diseases. Cioffi G, Viapiana O, Tarantini L, Orsolini G, Idolazzi L, Ognibeni F, Dalbeni A, Gatti D, **Fassio A**, Adami G, Rossini M, Giollo A. Arthritis Res Ther. 2021

#### 4.2 AUTHORSHIP PARTECIPATION IN BOOKS

1. Algodistrofia dalla A alla Z. AAVV, 2017 - Medical Star edizioni. Capitolo 4, "Algodistrofia e fratture"
2. Trauma. La gestione del Paziente. AAVV, 2018 – Griffin Edizioni. Capitolo 12, "L'algodistrofia post-traumatica"

#### 4.3 ABSTRACTS

1. Biomarkers nel trattamento dell'osteoporosi. D. Gatti. L. Idolazzi; S. Tamanini; A. Fassio; O. Viapiana; E. Fracassi; M. Rossini; S. Adami U.O. Reumatologia, Dipartimento Medicina, Università di Verona, Congresso SIR 2013 Napoli
2. L'iperparatiroidismo primitivo produce una dissociazione tra gli inibitori del sistema wnt – beta catenina. Viapiana O, Idolazzi L, Dartizio C, Benini C, Tonetta S, Povino MR, Liuzza S, Bakri J, Fassio A, Tripi G, Fracassi E, Gatti D, Adami S. XI Congresso Nazione SIOMMMS, Roma 2011
3. Il trattamento con neridronato produce un aumento dei livelli circolanti di sclerostina. L. Idolazzi, C. Dartizio, C. Benini, S. Tonetta, S. Tamanini,

C. Caimmi, M.R. Povino, A. Fassio, O. Viapiana, D. Gatti, S. Adami. XI Congresso Nazione SIOMMMS, Roma 2011

4. One year in bone. D. Gatti, A Fassio. XVI Congresso Nazione SIOMMMS, Roma 2016

#### **4.4 ORAL COMMUNICATIONS**

1. Teriparatide and Denosumab combination therapy and skeletal metabolism. A. Fassio; D. Gatti; O. Viapiana; V. Braga; L. Idolazzi; G. Adami; M. Rossini. EULAR 2016 London
2. Open-label, not controlled, three-year study of the effect of infusion of neridronate in patients with osteogenesis imperfecta. A. Fassio; D. Gatti. Congress Ol in 2016 – latest development in osteogenesis imperfecta – Lisbon
3. COMPARISON OF GLUCOCORTICOID TREATMENT, TNF OR IL-6 BLOCKADE ON THE ACUTE EFFECTS ON BONE TURNOVER MARKERS AND WNT INHIBITORS IN EARLY RHEUMATOID ARTHRITIS: A PILOT STUDY. A. Fassio, et al. SIOMMMS – 26/oct/2019, Bologna, Italy
4. THE EFFECTS OF THREE DIFFERENT VITAMIN D3 SUPPLEMENTATION REGIMENS IN DEFICIENT SUBJECTS - A RANDOMIZED OPEN-LABEL PARALLEL GROUP STUDY – 08/may/2021 European Calcified Tissue Society 2021 conference

#### **4.5 PRIZES**

1. Premio di Ricerca SIOMMMS 2019 per il progetto: “Evaluation of bone modulators and turnover markers in different form of osteoporosis and during pharmacological and non-pharmacological treatment”

#### **5. REVIEWING ACTIVITY FOR SCIENTIFIC PUBLICATIONS, for the following journals:**

1. Nature Reviews Rheumatology
2. Rheumatology
3. Clinical Rheumatology
4. Current Pharmacological Design
5. Journal of Translational Medicine

6. International Immunopharmacology
7. Scandinavian Journal of Rheumatology
8. International immunopharmacology
9. Osteoporosis International

## **6. INVOLVEMENT IN CLINICAL TRIALS**

Attended multiple training courses in ICH-GCP.

1.     Protocollo CAIN457F2306 – Novartis  
Subinvestigator
2.     Protocol Naimes/32 – Abiogen  
Subinvestigator
3.     Protocol MK 8808-002 – Parexel  
Subinvestigator

## **7. EDUCATIONAL COURSES**

- V Course on Radio Rheumatology – SIR Course – Camogli (GE) 2012
- Synovial Fluid Analysis – SIR Course – Praglia (PD) 2014
- Osteoporosis Management – Valeggio sul Mincio (VR) 2011
- ECOSTAR project for monitoring the RA damage with ultrasonography
- 13° Corso di Medicina Manuale Ortopedica ed Osteopatica secondo Robert Maigne – AIRAS, Padova, 2016/2017
- Seminari di perfezionamento in Medicina Manuale Ortopedica ed Osteopatica secondo Robert Maigne: “le tecniche Neuromuscolari” e “manipolazioni vertebrali complementari” – AIRAS, Padova, 2017
- Diplome interuniversitaire: Medecine Manuelle-Osteopathie 2. Université Paris Descartes – Paris, 2017-2018
- Musculoskeletal Imaging Winter School – ICSS CROB, Rionero In Vulture (PZ), 21-25/01/2019

## 8. LECTURES AND TEACHING ACTIVITY

- Tendinopatie, dall'overuse all'infiammazione, "Acido ialuronico, tendini e legamenti danneggiati: quando e quale". Torino – Juventus Stadium 2015
- Tendinopatie, dall'overuse all'infiammazione, "Il punto di vista degli specializzandi in ortopedia, reumatologia, fisioterapia e medicina dello sport". Maranello – Museo Ferrari, 2016
- Corso di aggiornamento Nr-axSpA contest, Milano 21/09/2017 – Presentazione di caso clinico
- Verona University Medical School: Summer School (1st Edition - 2-6 October 2017) BONE ACROSS THE LIFE SPAN: FUNCTION, DYSFUNCTION AND THERAPY – 06/10/2017 - Effects of movement on bone remodeling
- Corso derma-reuma; la gestione multidisciplinare della malattia psoriasica. "Il trattamento della malattia psoriasica, il punto di vista del dermatologo e del reumatologo". Camogli, 03-04/11/2017
- Corso residenziale "I segni Ultrasonografici di malattia nell'Artrite Psoriasica e nelle Spondiloartriti" – OCM Verona, 04/07/2017
- Corso residenziale "Basic Course di Ecografia in Reumatologia" – Policlinico GB Rossi Verona, 15-16/09/2017
- L'osteoporosi, dalla diagnosi alla terapia – Moena, 30/09/2017.
- Update su: ecografia articolare, malattie osteoarticolari e vitamina D, malattie osteoarticolari e dolore. Lazise 1-2/12/2017
- Verona University Medical School: Summer School (2st Edition – 17-21 September 2018) THE BASICS OF BONE IN HEALTH AND DISEASE: A JOURNEY FROM LAB BENCH TO BEDSIDE- Effects of movement on bone remodelling. Presentation on "Anabolic Drugs" (20/09/2018).
- One Year in Therapy – Rheumatic Diseases. 12/12/2018. Lectures: "Osteomalacia", "Anabolic Drugs".
- Update su: ecografia articolare, patologie scheletriche e dolore, vitamina D, osteoporosi e bisfosfonati. Lazise 14-15/12/2018 (lecturer, chief advisor)
- Osteoimmunology Course, Policlinico "G.B. Rossi", Verona. 1-2/03/2019
- Osteoporosi Update – Moena 04/05/2019. **Responsabile scientifico.**

## **9. MAIN SCIENTIFIC INTERESTS**

- Imaging in Rheumatology, musculoskeletal ultrasound and related interventional procedures
- Osteoporosis
- Osteoimmunology
- Mineral metabolic and bone diseases
- Rare and gene related pathologies (osteogenesis imperfecta)
- Psoriatic and Rheumatoid arthritis
- Early Arthritis

## **10. GENERAL SKILLS**

Foreign language: English

<b>Reading skills</b>	<b>Writing skills</b>	<b>Verbal skills</b>
Excellent	Excellent	Excellent

**Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali ".**

Verona, 11/05/2021

**Dott Angelo Fassio**  
**Dipartimento di Medicina**  
**UOC Reumatologia**  
**Università di Verona**  
**Tel. +393332811723**

e-mail **angelo.fassio@yahoo.it**